{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:44:05Z","timestamp":1793454245407,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2016-01355"],"award-info":[{"award-number":["2016-01355"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01292"],"award-info":[{"award-number":["2019-01292"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the use of baricitinib and tofacitinib by Swedish RA patients and to compare their effectiveness with that of biologic DMARDs (bDMARDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RA patients who initiated baricitinib (n\u2009=\u20091420), tofacitinib (n\u2009=\u2009316), abatacept (n\u2009=\u20091050), IL-6 inhibitors (IL-6is; n\u2009=\u2009849), rituximab (n\u2009=\u20091101) or TNF inhibitors (TNFis; n\u2009=\u20096036) between January 2017 and November 2019 were followed for a minimum of 1\u2009year using data from several linked Swedish national registers. Proportions reaching a good EULAR 28-joint DAS (DAS28) response, HAQ Disability Index (HAQ-DI) improvement &amp;gt;0.2 units and Clinical Disease Activity Index (CDAI) remission were compared at 1\u2009year, imputing discontinued treatments as \u2018non-response\u2019. Additionally, we compared drug retention and changes in DAS28, HAQ-DI and CDAI from baseline to 3\u2009months after treatment initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>On average, baricitinib, and particularly tofacitinib, were initiated as later lines of therapy and more frequently as monotherapy compared with rituximab and TNFi. Adjusted 1\u2009year response proportions were consistently lower on TNFi compared with baricitinib, with differences of \u22124.3 percentage points (95% CI \u22128.7, 0.1) for good EULAR response, \u22129.9 (\u221214.4 to \u22125.4) for HAQ-DI improvement and \u22126.0 (\u22129.8 to \u22122.2) for CDAI remission. Comparisons with non-TNFi bDMARDs also favoured baricitinib, but not consistently. Treatment responses for tofacitinib were only marginally lower than those for baricitinib and generally similar to those of bDMARDs, with precision limited by low power. Comparisons of drug retention and changes in disease activity from baseline to 3\u2009months supported the 1\u2009year findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Baricitinib and tofacitinib showed at least equivalent effectiveness compared with bDMARDs after exploring several different effectiveness measures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac068","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T20:14:05Z","timestamp":1643314445000},"page":"3952-3962","source":"Crossref","is-referenced-by-count":39,"title":["Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-1525","authenticated-orcid":false,"given":"Andrei","family":"Barbulescu","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet"},{"name":"Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[{"name":"Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital"},{"name":"Rheumatology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Forsblad-d\u2019Elia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alf","family":"Kastbom","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-9348","authenticated-orcid":false,"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-2290","authenticated-orcid":false,"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[{"name":"Rheumatology, Department of Clinical Sciences, Malm\u00f6, Lund University , Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2022100812091388100_keac068-B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022100812091388100_keac068-B2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022100812091388100_keac068-B3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13075-020-02391-w","article-title":"Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients","volume":"22","author":"Bywall","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022100812091388100_keac068-B4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022100812091388100_keac068-B5","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022100812091388100_keac068-B6","article-title":"Safety and efficacy of tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: results from a phase 3b\/4 randomized safety trial","volume":"73(Suppl 10","author":"Ytterberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022100812091388100_keac068-B7","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"2022100812091388100_keac068-B8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022100812091388100_keac068-B9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"2022100812091388100_keac068-B10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022100812091388100_keac068-B11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four\u2013month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022100812091388100_keac068-B12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"2022100812091388100_keac068-B13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"2022100812091388100_keac068-B14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2022100812091388100_keac068-B15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022100812091388100_keac068-B16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2022100812091388100_keac068-B17","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022100812091388100_keac068-B18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"2022100812091388100_keac068-B19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022100812091388100_keac068-B20","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s10067-020-05021-7","article-title":"Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia","volume":"39","author":"Bird","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2022100812091388100_keac068-B21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3899\/jrheum.191252","article-title":"Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study","volume":"48","author":"Fisher","year":"2021","journal-title":"J Rheumatol"},{"key":"2022100812091388100_keac068-B22","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2022100812091388100_keac068-B23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022100812091388100_keac068-B24","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"40","author":"Ebina","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2022100812091388100_keac068-B25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","article-title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2022100812091388100_keac068-B26","first-page":"S-147","article-title":"The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data","volume":"32","author":"Eriksson","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022100812091388100_keac068-B27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic Health Registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2022100812091388100_keac068-B28","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022100812091388100_keac068-B29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/annrheumdis-2017-212395","article-title":"Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics","volume":"77","author":"Frisell","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022100812091388100_keac068-B30","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/aje\/kwm223","article-title":"A modified least-squares regression approach to the estimation of risk difference","volume":"166","author":"Cheung","year":"2007","journal-title":"Am J Epidemiol"},{"key":"2022100812091388100_keac068-B31","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/sim.3618","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"White","year":"2009","journal-title":"Stat Med"},{"key":"2022100812091388100_keac068-B32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"2022100812091388100_keac068-B33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis","volume":"6","author":"Reed","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2022100812091388100_keac068-B34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022100812091388100_keac068-B35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"key":"2022100812091388100_keac068-B36","author":"Center for Drug Evaluation and Research"},{"key":"2022100812091388100_keac068-B37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-eular.774","article-title":"Op0122 Comparative effectiveness of JAKi versus bDMARDS; a nationwide study in RA","volume":"80","author":"Barbulescu","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac068\/42559602\/keac068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/3952\/46382889\/keac068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/3952\/46382889\/keac068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:13:36Z","timestamp":1665231216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/10\/3952\/6520812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac068","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,2,3]]}}}